CD209a Monoclonal Antibody (MMD3), eFluor™ 660, eBioscience™, Invitrogen™

Description

• This MMD3 MAb recognizes mouse CD209a, which is also known as DC-SIGN
• CD209a is a type II transmembrane C-type lectin expressed on a subset of dendritic cells, including some CD4+, CD8- and plasmacytoid pre-dendritic cells
• Studies indicate that CD209a expression can vary according to the activation state of the host
• Moreover, CD209a is down-regulated in spleen-derived dendritic cell cultures supplemented with GM-CSF
• CD209a is involved in mediating the innate immune response by binding microbial carbohydrates
• Cross-blocking studies suggest that MMD3 recognizes a different a different epitope from LWC06 and 5H10
• This gene encodes a transmembrane receptor and is often referred to as DC-SIGN because of its expression on the surface of dendritic cells and macrophages
• The encoded protein is involved in the innate immune system and recognizes numerous evolutionarily divergent pathogens ranging from parasites to viruses with a large impact on public health
• The protein is organized into three distinct domains: an N-terminal transmembrane domain, a tandem-repeat neck domain and C-type lectin carbohydrate recognition domain
• The extracellular region consisting of the C-type lectin and neck domains has a dual function as a pathogen recognition receptor and a cell adhesion receptor by binding carbohydrate ligands on the surface of microbes and endogenous cells
• The neck region is important for homo-oligomerization which allows the receptor to bind multivalent ligands with high avidity
• Variations in the number of 23 amino acid repeats in the neck domain of this protein are rare but have a significant impact on ligand binding ability
• This gene is closely related in terms of both sequence and function to a neighboring gene (GeneID 10332; often referred to as L-SIGN)
• DC-SIGN and L-SIGN differ in their ligand-binding properties and distribution
• Alternative splicing results in multiple variants.